{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:34:29Z","timestamp":1787315669924,"version":"build-2736575974"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T00:00:00Z","timestamp":1614729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T00:00:00Z","timestamp":1614729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"crossref","award":["C569\/A5032"],"award-info":[{"award-number":["C569\/A5032"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"crossref","award":["C569\/A16891"],"award-info":[{"award-number":["C569\/A16891"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"crossref","award":["C8162\/A26893"],"award-info":[{"award-number":["C8162\/A26893"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004325","name":"Astrazeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002653","name":"Yorkshire Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014653","name":"NIHR Manchester Biomedical Research Centre","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Prevent Breast Cancer"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We investigated the association between body mass index (BMI) and breast cancer risk in women at increased risk of breast cancer receiving tamoxifen or anastrozole compared with placebo using data from the International Breast Cancer Intervention Studies [IBIS-I (tamoxifen) and IBIS-II (anastrozole)].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Baseline BMI was calculated from nurse assessed height and weight measurements for premenopausal (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20093138) and postmenopausal (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20093731) women in IBIS-I and postmenopausal women in IBIS-II (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20093787). The primary endpoint was any breast cancer event (invasive and ductal carcinoma in situ). We used Cox proportional hazards regression to calculate hazard ratios (HRs) for risk after adjustment for covariates.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There were 582 (IBIS-I) and 248 (IBIS-II) breast cancer events [median follow-up\u2009=\u200916.2\u00a0years (IQR 14.4\u201317.7) and 10.9\u00a0years (IQR 8.8\u201313.0), respectively]. In adjusted analysis, women with a higher BMI had an increased breast cancer risk in both IBIS-I [HR\u2009=\u20091.06 per 5\u00a0kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      (0.99\u20131.15),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.114] and in IBIS-II [HR per 5\u00a0kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20091.21 (1.09\u20131.35),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001]. In IBIS-I, the association between BMI and breast cancer risk was positive in postmenopausal women [adjusted HR per 5\u00a0kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20091.14 (1.03\u20131.26),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01] but not premenopausal women [adjusted HR per 5\u00a0kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090.97 (0.86\u20131.09),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.628]. There was no interaction between BMI and treatment group for breast cancer risk in either IBIS-I (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.62) or IBIS-II (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.55).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Higher BMI is associated with greater breast cancer risk in postmenopausal women at increased risk of the disease, but no effect was observed in premenopausal women. The lack of interaction between BMI and treatment group on breast cancer risk suggests women are likely to experience benefit from preventive therapy regardless of their BMI.<\/jats:p>\n                    <jats:p>\n                      <jats:italic>Trial registration<\/jats:italic>\n                      Both trials were registered [IBIS-I: ISRCTN91879928 on 24\/02\/2006, retrospectively registered (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.isrctn.com\/ISRCTN91879928\">http:\/\/www.isrctn.com\/ISRCTN91879928<\/jats:ext-link>\n                      ); IBIS-II: ISRCTN31488319 on 07\/01\/2005, retrospectively registered (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.isrctn.com\/ISRCTN31488319\">http:\/\/www.isrctn.com\/ISRCTN31488319<\/jats:ext-link>\n                      )]\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10549-021-06141-7","type":"journal-article","created":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T06:03:54Z","timestamp":1614751434000},"page":"215-223","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["The impact of body mass index on breast cancer incidence among women at increased risk: an observational study from the International Breast Intervention Studies"],"prefix":"10.1007","volume":"188","clinical-trial-number":[{"clinical-trial-number":"isrctn91879928","registry":"10.18810\/isrctn"},{"clinical-trial-number":"isrctn31488319","registry":"10.18810\/isrctn"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1983-4470","authenticated-orcid":false,"given":"Samuel G.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Sestak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle. A.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Harvie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Forbes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Cuzick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,3]]},"reference":[{"key":"6141_CR1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. https:\/\/doi.org\/10.3322\/caac.21492","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"6141_CR2","doi-asserted-by":"crossref","first-page":"635","DOI":"10.7326\/0003-4819-156-9-201205010-00006","volume":"156","author":"HD Nelson","year":"2012","unstructured":"Nelson HD, Zakher B, Cantor A, Fu R, Griffin J, O\u2019Meara ES et al (2012) Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. Ann Intern Med 156(9):635\u2013648","journal-title":"Ann Intern Med"},{"issue":"9","key":"6141_CR3","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1001\/jamaoncol.2016.6326","volume":"3","author":"NJ Engmann","year":"2017","unstructured":"Engmann NJ, Golmakani MK, Miglioretti DL, Sprague BL, Kerlikowske K (2017) Population-attributable risk proportion of clinical risk factors for breast cancer. JAMA Oncol 3(9):1228\u20131236","journal-title":"JAMA Oncol"},{"issue":"12","key":"6141_CR4","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1093\/aje\/kww145","volume":"184","author":"RM Tamimi","year":"2016","unstructured":"Tamimi RM, Spiegelman D, Smith-Warner SA, Wang M, Pazaris M, Willett WC et al (2016) Population attributable risk of modifiable and nonmodifiable breast cancer risk factors in postmenopausal breast cancer. Am J Epidemiol 184(12):884\u2013893","journal-title":"Am J Epidemiol"},{"issue":"8","key":"6141_CR5","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1056\/NEJMsr1606602","volume":"375","author":"B Lauby-Secretan","year":"2016","unstructured":"Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K et al (2016) Body fatness and cancer: viewpoint of the IARC Working Group. N Engl J Med 375(8):794\u2013798","journal-title":"N Engl J Med"},{"key":"6141_CR6","unstructured":"World Cancer Research Fund\/American Institute for Cancer Research (2018) Diet, nutrition, physical activity and breast cancer. https:\/\/www.wcrf.org\/sites\/default\/files\/Breast-cancer-report.pdf. Accessed 2 Mar 2021"},{"issue":"11","key":"6141_CR7","doi-asserted-by":"crossref","first-page":"e181771","DOI":"10.1001\/jamaoncol.2018.1771","volume":"4","author":"MJ Schoemaker","year":"2018","unstructured":"Premenopausal Breast Cancer Collaborative Group, Schoemaker MJ, Nichols HB, Wright LB, Brook MN, Jones ME et al (2018) Association of body mass index and age with subsequent breast cancer risk in premenopausal women. JAMA Oncol 4(11):e181771","journal-title":"JAMA Oncol"},{"issue":"2","key":"6141_CR8","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/obr.12627","volume":"19","author":"K Hidayat","year":"2018","unstructured":"Hidayat K, Yang C-M, Shi B-M (2018) Body fatness at a young age, body fatness gain and risk of breast cancer: systematic review and meta-analysis of cohort studies. Obes Rev 19(2):254\u2013268","journal-title":"Obes Rev"},{"issue":"3","key":"6141_CR9","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/jnci\/djq526","volume":"103","author":"XR Yang","year":"2011","unstructured":"Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL et al (2011) Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium Studies. J Natl Cancer Inst 103(3):250\u2013263","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"6141_CR10","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1001\/jamaoncol.2015.1546","volume":"1","author":"ML Neuhouser","year":"2015","unstructured":"Neuhouser ML, Aragaki AK, Prentice RL, Manson JE, Chlebowski R, Carty CL et al (2015) Overweight, obesity, and postmenopausal invasive breast cancer risk: a secondary analysis of the Women\u2019s Health Initiative Randomized Clinical Trials. JAMA Oncol 1(5):611\u2013621","journal-title":"JAMA Oncol"},{"issue":"3","key":"6141_CR11","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s10549-010-1116-4","volume":"123","author":"A Vrieling","year":"2010","unstructured":"Vrieling A, Buck K, Kaaks R, Chang-Claude J (2010) Adult weight gain in relation to breast cancer risk by estrogen and progesterone receptor status: a meta-analysis. Breast Cancer Res Treat 123(3):641\u2013649","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"6141_CR12","first-page":"1","volume":"109","author":"K Kerlikowske","year":"2016","unstructured":"Kerlikowske K, Gard CC, Tice JA, Ziv E, Cummings SR, Miglioretti DL (2016) Risk factors that Increase risk of estrogen receptor-positive and -negative breast cancer. J Natl Cancer Inst 109(5):1\u20135","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"6141_CR13","doi-asserted-by":"crossref","first-page":"R82","DOI":"10.1186\/bcr2727","volume":"12","author":"R Gramling","year":"2010","unstructured":"Gramling R, Lash TL, Rothman KJ, Cabral HJ, Silliman R, Roberts M et al (2010) Family history of later-onset breast cancer, breast healthy behavior and invasive breast cancer among postmenopausal women: a cohort study. Breast Cancer Res 12(5):R82","journal-title":"Breast Cancer Res"},{"key":"6141_CR14","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13058-018-1056-1","volume":"20","author":"JL Hopper","year":"2018","unstructured":"Hopper JL, Dite GS, MacInnis RJ, Liao Y, Zeinomar N, Knight JA et al (2018) Age-specific breast cancer risk by body mass index and familial risk: prospective family study cohort (ProF-SC). Breast Cancer Res 20:132","journal-title":"Breast Cancer Res"},{"issue":"4","key":"6141_CR15","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1158\/1940-6207.CAPR-11-0482","volume":"5","author":"RS Cecchini","year":"2012","unstructured":"Cecchini RS, Costantino JP, Cauley JA, Cronin WM, Wickerham DL, Land SR et al (2012) Body mass index and the risk for developing invasive breast cancer among high-risk women in NSABP P-1 and STAR breast cancer prevention trials. Cancer Prev Res 5(4):583\u2013592","journal-title":"Cancer Prev Res"},{"issue":"18","key":"6141_CR16","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","volume":"90","author":"B Fisher","year":"1998","unstructured":"Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90(18):1371\u20131388","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"6141_CR17","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","volume":"295","author":"VG Vogel","year":"2006","unstructured":"Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN et al (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295(23):2727\u20132741","journal-title":"JAMA"},{"issue":"19","key":"6141_CR18","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/jnci\/djg060","volume":"95","author":"JJ Dignam","year":"2003","unstructured":"Dignam JJ, Wieand K, Johnson KA, Fisher B, Xu L, Mamounas EP (2003) Obesity, Tamoxifen use, and outcomes in women with estrogen receptor\u2013positive early-stage breast cancer. J Natl Cancer Inst 95(19):1467\u20131476","journal-title":"J Natl Cancer Inst"},{"issue":"32","key":"6141_CR19","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1200\/JCO.2011.40.8666","volume":"30","author":"M Ewertz","year":"2012","unstructured":"Ewertz M, Gray KP, Regan MM, Ejlertsen B, Price KN, Th\u00fcrlimann B et al (2012) Obesity and risk of recurrence or death after adjuvant endocrine therapy with Letrozole or Tamoxifen in the Breast International Group 1\u201398 Trial. J Clin Oncol 30(32):3967\u20133975","journal-title":"J Clin Oncol"},{"issue":"21","key":"6141_CR20","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1200\/JCO.2009.27.2021","volume":"28","author":"I Sestak","year":"2010","unstructured":"Sestak I, Distler W, Forbes JF, Dowsett M, Howell A, Cuzick J (2010) Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol 28(21):3411\u20133415","journal-title":"J Clin Oncol"},{"issue":"19","key":"6141_CR21","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1200\/JCO.2010.33.2585","volume":"29","author":"G Pfeiler","year":"2011","unstructured":"Pfeiler G, K\u00f6nigsberg R, Fesl C, Mlineritsch B, Stoeger H, Singer CF et al (2011) Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 Trial. J Clin Oncol 29(19):2653\u20132659","journal-title":"J Clin Oncol"},{"issue":"3","key":"6141_CR22","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/bjc.2013.367","volume":"109","author":"M Gnant","year":"2013","unstructured":"Gnant M, Pfeiler G, St\u00f6ger H, Mlineritsch B, Fitzal F, Balic M et al (2013) The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial. Br J Cancer 109(3):589\u2013596","journal-title":"Br J Cancer"},{"issue":"2","key":"6141_CR23","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10549-014-3091-7","volume":"147","author":"SJ Ioannides","year":"2014","unstructured":"Ioannides SJ, Barlow PL, Elwood JM, Porter D (2014) Effect of obesity on aromatase inhibitor efficacy in postmenopausal, hormone receptor-positive breast cancer: a systematic review. Breast Cancer Res Treat 147(2):237\u2013248","journal-title":"Breast Cancer Res Treat"},{"issue":"21","key":"6141_CR24","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1200\/JCO.2010.29.5113","volume":"28","author":"PJ Goodwin","year":"2010","unstructured":"Goodwin PJ, Pritchard KI (2010) Obesity and hormone therapy in breast cancer: an unfinished puzzle. J Clin Oncol 28(21):3405\u20133407","journal-title":"J Clin Oncol"},{"issue":"1","key":"6141_CR25","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1470-2045(14)71171-4","volume":"16","author":"J Cuzick","year":"2015","unstructured":"Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A et al (2015) Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol 16(1):67\u201375","journal-title":"Lancet Oncol"},{"issue":"10218","key":"6141_CR26","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(19)32955-1","volume":"395","author":"J Cuzick","year":"2020","unstructured":"Cuzick J, Sestak I, Forbes JF, Dowsett M, Cawthorn S, Mansel RE et al (2020) Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. Lancet 395(10218):117\u2013122","journal-title":"Lancet"},{"issue":"4","key":"6141_CR27","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/jnci\/djk049","volume":"99","author":"J Cuzick","year":"2007","unstructured":"Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K et al (2007) Long-term results of tamoxifen prophylaxis for breast cancer: 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 99(4):272\u2013282","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"6141_CR28","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/sim.1668","volume":"23","author":"J Tyrer","year":"2004","unstructured":"Tyrer J, Duffy SW, Cuzick J (2004) A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 23(7):1111\u20131130","journal-title":"Stat Med"},{"issue":"9612","key":"6141_CR29","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0140-6736(08)60269-X","volume":"371","author":"AG Renehan","year":"2008","unstructured":"Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371(9612):569\u2013578","journal-title":"Lancet"},{"issue":"2","key":"6141_CR30","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1001\/jama.296.2.193","volume":"296","author":"AH Eliassen","year":"2006","unstructured":"Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE (2006) Adult weight change and risk of postmenopausal breast cancer. JAMA 296(2):193\u2013201","journal-title":"JAMA"},{"issue":"9","key":"6141_CR31","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/jnci\/djp068","volume":"101","author":"R Ballard-Barbash","year":"2009","unstructured":"Ballard-Barbash R, Hunsberger S, Alciati MH, Blair SN, Goodwin PJ, McTiernan A et al (2009) Physical activity, weight control, and breast cancer risk and survival: clinical trial rationale and design considerations. J Natl Cancer Inst 101(9):630\u2013643","journal-title":"J Natl Cancer Inst"},{"key":"6141_CR32","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/obr.12028","volume":"8","author":"A Amadou","year":"2013","unstructured":"Amadou A, Ferrari P, Muwonge R, Moskal A, Biessy C, Romieu I et al (2013) Overweight, obesity and risk of premenopausal breast cancer according to ethnicity: a systematic review and dose-response meta-analysis. Obes Rev 8:665\u2013678","journal-title":"Obes Rev"},{"issue":"1","key":"6141_CR33","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13058-018-1056-1","volume":"20","author":"JL Hopper","year":"2018","unstructured":"Hopper JL, Dite GS, MacInnis RJ, Liao Y, Zeinomar N, Knight JA et al (2018) Age-specific breast cancer risk by body mass index and familiar risk: prospective family cohort study (ProF-SC). Breast Cancer Res 20(1):132","journal-title":"Breast Cancer Res"},{"issue":"3","key":"6141_CR34","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1046\/j.1467-789X.2003.00108.x","volume":"4","author":"M Harvie","year":"2003","unstructured":"Harvie M, Hooper L, Howell AH (2003) Central obesity and breast cancer risk: a systematic review. Obes Rev 4(3):157\u2013173","journal-title":"Obes Rev"},{"issue":"3","key":"6141_CR35","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10552-015-0709-y","volume":"27","author":"J De Ridder","year":"2016","unstructured":"De Ridder J, Juli\u00e1n-Alm\u00e1rcegui C, Mullee A, Rinaldi S, Van Herck K, Vicente-Rodr\u00edguez G et al (2016) Comparison of anthropometric measurements of adiposity in relation to cancer risk: a systematic review of prospective studies. Cancer Causes Control 27(3):291\u2013300","journal-title":"Cancer Causes Control"},{"issue":"5","key":"6141_CR36","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/ijc.31394","volume":"143","author":"W Guo","year":"2018","unstructured":"Guo W, Key TJ, Reeves GK (2018) Adiposity and breast cancer risk in postmenopausal women: results from the UK Biobank prospective cohort. Int J Cancer 143(5):1037\u20131046","journal-title":"Int J Cancer"},{"key":"6141_CR37","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/obr.12627","volume":"19","author":"K Hidyat","year":"2018","unstructured":"Hidyat K, Yang CM, Shi BM (2018) Body fatness at a young age, body fatness gain and risk of breast cancer: systematic review and meta-analysis of cohort studies. Obes Rev 19:254\u2013268","journal-title":"Obes Rev"},{"key":"6141_CR38","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejca.2016.02.028","volume":"60","author":"SH Njor","year":"2016","unstructured":"Njor SH, von Euler-Chelpin M, Tj\u00f8nneland A, Vejborg I, Lynge E (2016) Body weight and sensitivity of screening mammography. Eur J Cancer 60:93\u2013100","journal-title":"Eur J Cancer"},{"issue":"13","key":"6141_CR39","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1093\/jnci\/djj262","volume":"98","author":"N Abramson","year":"2006","unstructured":"Abramson N, Costantino JP, Garber JE, Berliner N, Wickerham DL, Wolmark N (2006) Effect of Factor V Leiden and prothrombin G20210\u2013>A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial. J Natl Cancer Inst 98(13):904\u2013910","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"6141_CR40","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/annonc\/mdv590","volume":"27","author":"SG Smith","year":"2016","unstructured":"Smith SG, Sestak I, Forster A, Partridge A, Side L, Wolf MS et al (2016) Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis. Ann Oncol 27(4):575\u2013590","journal-title":"Ann Oncol"},{"issue":"9","key":"6141_CR41","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1158\/1940-6207.CAPR-11-0172","volume":"4","author":"SR Land","year":"2011","unstructured":"Land SR, Cronin WM, Wickerham L, Constantino JP, Christian NJ, Klein WMP et al (2011) Cigarette smoking, obesity, physical activity, and alcohol use as predictors of chemoprevention adherence in the National Surgical Adjuvant Breast and Bowel Project P-1 Breast Cancer Prevention Trial. Cancer Prev Res 4(9):1393\u20131400","journal-title":"Cancer Prev Res"},{"issue":"23","key":"6141_CR42","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1200\/JCO.2016.71.7439","volume":"35","author":"SG Smith","year":"2017","unstructured":"Smith SG, Sestak I, Howell A, Forbes J, Cuzick J (2017) Participant-reported symptoms and their effect on long-term adherence in the International Breast Cancer Intervention Study I (IBIS I). J Clin Oncol 35(23):2666\u20132673","journal-title":"J Clin Oncol"},{"issue":"2","key":"6141_CR43","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/annonc\/mdx713","volume":"29","author":"I Sestak","year":"2018","unstructured":"Sestak I, Smith SG, Howell A, Forbes JF, Cuzick J (2018) Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II. Ann Oncol 29(2):504\u2013509","journal-title":"Ann Oncol"},{"issue":"2","key":"6141_CR44","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s10549-012-2085-6","volume":"134","author":"I Sestak","year":"2012","unstructured":"Sestak I, Harvie M, Howell A, Forbes JF, Dowsett M, Cuzick J (2012) Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer. Breast Cancer Res Treat 134(2):727\u2013734","journal-title":"Breast Cancer Res Treat"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06141-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-021-06141-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06141-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T11:56:42Z","timestamp":1628596602000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-021-06141-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,3]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["6141"],"URL":"https:\/\/doi.org\/10.1007\/s10549-021-06141-7","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,3]]},"assertion":[{"value":"13 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MM is inventor and shareholder at Dietary Assessment Limited. SS, IS, MH, AH, JF and JC declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of local ethics committees for each participating site (IBIS-I trial) and the UK North West Multicentre Research Ethics Committee (IBIS-II) and with the 1964 Helsinki declaration and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}